![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
The prostanoids are commonly used in the treatment of glaucoma. They have been shown to effectively reduce intraocular pressure with a relatively benign side-effect profile. Tafluprost is the newest member of the prostanoid family used in the treatment of glaucoma, and it is also the first prostanoid to be released in a preservative-free formulation. Early data suggest that it is as effective as the other prostanoids. The objective of this article is to detail the development and subsequent early testing of tafluprost.
Keywords::
Financial & competing interests disclosure
J Tsai is a consultant for Alcon, Allergan, Inspire, Merck, QLT and Rhodes. He was also an investigator in a Phase III clinical trial from Merck on preservative-free tafluprost. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.